Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Pancreatic Cancer Early Detection for People at High Risk
Printer Friendly Page Pancreatic Cancer Early Detection for People  at High Risk

Pancreatic Cancer Early Detection for People at High Risk identifier:

Registry and biobank for high risk people undergoing pancreatic cancer screening

Study Contact Information:

For additional information, contact:
Contact: Patrick Kelly, MPH: 7346654108        [email protected]
Contact: John Graff, PhD:  7346654108        [email protected]

Pancreatic Cancer Early Detection for People at High Risk

About the Study

The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal ().

What the Study Involves:

Study participation may include:

  • Providing a blood sample (about 4 tablespoons) at each clinic visit throughout the course of the study.
  • Providing a and RNA sample that will be extracted from blood, saliva, or cheek swab
  • Providing medical and family history information to be included in the study database
  • Providing permission to access your medical records, retrieve results from routine clinical care, such as genetic testing, imaging studies (eg MRI/MRCP, endoscopic , CT abdomen)
  • A baseline clinical visit and up to 2 visits per year, depending on the frequency of your clinical care pancreas cancer screening
  • Providing a blood sample and medical records at any event driven clinical follow up of abnormal findings with imaging and lab studies
  • If you are diagnosed with pancreatic cancer, you will be asked to donate extra tissue at the time of clinical biopsies or surgeries

Study Locations


  • Duarte
    City of Hope
    Contact: Anita Menchaca       [email protected]   
    Lead researcher: James Lin         
    Lead researcher: Greg Idos         
  • La Jolla
    UC San Diego Moores Cancer Center
    Contact: Shirley Sarno       [email protected]   
    Lead researcher: Andy Lowy         
    Lead researcher: Joy Liau         
  • Los Angeles
    Cedars-Sinai Medical Center
    Contact: Liliana Bancila    310-423-3872    [email protected]   
    Lead researcher: Srinivas Gaddam         


  • New Haven
    Yale University
    Contact: Scott Merenda       [email protected]   
    Lead researcher: James Farrell         


  • Jacksonville
    Mayo Clinic, Jacksonville
    Contact: Guillermo Pradieu       [email protected]   
    Lead researcher: Yan Bi         
    Lead researcher: Michael Wallace
  • Miami
    University of Miami
    Contact: Elena Cortizas       [email protected]   
    Contact: Anna Yabloch       [email protected]   
    Lead researcher: Dan Sussman         
    Lead researcher: Nipun Merchant         
  • Tampa
    Moffitt Cancer Center
    Lead researcher: Jenny Permuth


  • Chicago
    University of Chicago Medicine
    Principal Investigator: Sonia Kupfer         


  • Boston
    Massachusetts General Hospital
    Contact: Danielle Lynch       [email protected]   
    Lead researcher: Daniel Chung
  • Worcester
    Umass Memorial Medical Center
    Contact: Cara Gregoire       [email protected]   
    Lead researcher: James Lindberg         


  • Ann Arbor
    University of Michigan
    Contact: Sarah Volk       [email protected]   
    Contact: Erika Koeppe       [email protected]   
    Lead researcher: Elena Stoffel         
    Lead researcher: Rich Kwon         


  • Omaha
    University of Nebraska Medical Center
    Contact: Suzanne Wessling       [email protected]   
    Lead researcher: Kelsey Klute         

New York

  • New York
    New York University Langone Health
    Contact: Jessica Everett       [email protected]   
    Contact: Jennifer Chun Kim       [email protected]   
    Lead researcher: Diane Simeone, MD         
  • New York
    Icahn School of Medicine At Mount Sinai
    Contact: Arielle Labiner       [email protected]   
    Lead researcher: Aimee Lucas         
  • New York
    Columbia University Irving Medical Center
    Contact: Tiffany Lam       [email protected]   
    Principal Investigator: Fay Kastrinos        
  • Rochester 
    University of Rochester Medical Center
    Contact: Krystle Bittner       [email protected]   
    Lead researcher: Darren Carpizo         
    Lead researcher: Vivek Kaul         


  • Portland
    Oregon Health & Science University
    Contact: Dove Keith       [email protected]   
    Lead researcher: Aaron Grossberg         
    Lead researcher: Brett Sheppard         
    Lead researcher: Rosie Sears         


  • Philadelphia
    University of Pennsylvania
    Contact: Danny Clay       [email protected]   
    Lead researcher: Bryson Katona         
  • Pittsburgh
    University of Pittsburgh Medical Center (Upmc)
    Contact: Beth Dudley       [email protected]   
    Lead researcher: Randy Brand         


  • Houston
    MD Anderson Center
    Contact: Florencia McAllister       [email protected]   
    Lead researcher: Florencia McAllister         


  • Salt Lake City
    Huntsman Cancer Institute
    Contact: Jo Anson       [email protected]   
    Lead researcher: Joanne Jeter         


  • Fairfax
    Inova Schar Cancer Institute
    Contact: Stephanie Van Bebber    571-472-4724    [email protected]   
    Lead researcher: Raymond Wadlow, MD         


  • Seattle
    University of Washington
    Contact: Lisa Ann Lai       [email protected]   
    Lead researcher: Teri Brentnall  

Additional sites are open in Canada, Israel, Italy, Spain, and the United Kingdom. See for the full list of open sites.        

This Study is Open To:

The study will enroll people from the following groups who present for clinical evaluation and assessment of risk at any of the participating sites can be offered participation in the PRECEDE study:

Group 1:

Individuals without personal diagnosis of meeting any of the following criteria:

  • 2 or more relatives with on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age: 50 or older or 10 or more years younger than earliest in family at time of diagnosis.
  • 2 affected with pancreatic cancer; age: 50 or older or 10 years younger than earliest pancreatic cancer  in family
  • in , , , , , , , , AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest pancreatic cancer in family
  • Familial Atypical Moles and Malignant Melanoma (FAMMM) with in CDKN2A; age: 40 or older
  • Peutz-Jegher syndrome with an inherited mutation; age: 35 or older
  • Hereditary pancreatitis with and inherited PRSS1 mutation and history of pancreatitis; age: 40 or older

Group 2

Individuals without a personal diagnosis  of meeting any of the following criteria:

  • , , , or inherited mutation regardless of family history, age: 50 or older
  • 2+ relatives with pancreatic cancer on the same side of family, any degree of relation, not meeting other criteria above; age: 50 or older or 10 years younger than earliest pancreatic cancer in family
  • 1 first degree relative with pancreatic cancer at or younger than age 45; age: up to 10 years younger than diagnosis in family member

Group 3

  • Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)

Group 4

  • Individuals without history of presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.

Group 5

  • Individuals without history of who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.

Group 6

Individuals with a personal history of meeting any of the following criteria:

  • Family history includes at least one first degree relative with , or 2 relatives with who are first degree related to each other
  • Personal or family history of a pathogenic or likely pathogenic germline variant in , , , CDKN2A, , , , , ,PMS2, PRSS1,
  • Diagnosed ≤ age 45

Cyst Group

  • Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of , no known pathogenic germline variants linked to risk)
This Study is Not Open To:

Individuals not meeting the criteria above are not eligible to participate.